{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-014942","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2022-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.448385+00:00","generated_at":"2026-06-25T07:45:15.751906+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anebulo appoints Kenneth Cundy as CSO; $350K salary, options, milestone vesting","bullets":["Dr. Cundy appointed CSO effective May 20, 2022; base salary $350,000, annual bonus up to 30%.","Receives option for 233,446 shares vesting quarterly over 4 years.","Additional option for 116,273 shares vests upon FDA approval of lead candidate ANEB-001.","Severance: 9 months' base salary plus COBRA for up to 12 months if terminated without cause.","Cundy previously CSO at CohBar and XenoPort; coinventor of tenofovir and Nanocrystal technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-014942","json":"https://secwatch.observer/filing/0001493152-22-014942.json","markdown":"https://secwatch.observer/filing/0001493152-22-014942.md","text":"https://secwatch.observer/filing/0001493152-22-014942.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222014942/0001493152-22-014942-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222014942/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T07:45:15.751906+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2be0e38231","claim":"Kenneth C. Cundy was appointed as Chief Scientific Officer at Anebulo Pharmaceuticals, Inc..","evidence_excerpt":"On May 24, 2022, Anebulo Pharmaceuticals, Inc. announced that Kenneth C. Cundy has been appointed as the Chief Scientific Officer of our company effective May 20, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315222014942/0001493152-22-014942-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}